Product Information
CARBIDOPA-LEVO ER 50-200 TAB is a generic product labeled by Advagen Pharma Ltd., priced at $0.1796 per EA under NDC 72888015630. Its NADAC has been published 82 times since Mar 12, 2025.
FDA first approved this application on Jun 4, 2024. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
50; 200 mg/1; mg/1
Manufacturer
Advagen Pharma Ltd.NDC
72888015630
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CARBIDOPA; LEVODOPAApproval Type
Generic (ANDA)
FDA Application
ANDA217482FDA Approved
6/4/2024
TE Code
AB
On Market Since
6/4/2024
Pharmacological Classes
Price Statistics
The NADAC for CARBIDOPA-LEVO ER 50-200 TAB has been published 82 times since Mar 12, 2025, and over the history we have for it it has declined 6.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1796 per EA |
|---|---|
| All-time high | $0.2186 (Aug 13, 2025) |
| All-time low | $0.1676 (Jul 22, 2026) |
| 52-week high | $0.2057 |
| 52-week low | $0.1676 |
| Median price | $0.1898 |
| Average price | $0.1939 |
| Largest weekly change | +8.1% (Mar 19, 2025) |
| Weeks tracked | 82 |
| Tracking since | Mar 12, 2025 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Advagen Pharma Ltd. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Carbidopa and levodopa market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aromatic Amino Acid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CARBIDOPA-LEVO ER 50-200 TAB?
The current National Average Drug Acquisition Cost (NADAC) for CARBIDOPA-LEVO ER 50-200 TAB, manufactured by Advagen Pharma Ltd., is $0.1796 per EA (NDC 72888015630), effective Sep 30, 2026.
How has the price of CARBIDOPA-LEVO ER 50-200 TAB changed over time?
Over the history we have for it, the NADAC for CARBIDOPA-LEVO ER 50-200 TAB has declined 6.9%. It has been tracked across 82 weekly CMS publications since Mar 12, 2025.
What are the highest and lowest recorded NADAC prices for CARBIDOPA-LEVO ER 50-200 TAB?
Since Mar 12, 2025, the NADAC for CARBIDOPA-LEVO ER 50-200 TAB has ranged from a low of $0.1676 (Jul 22, 2026) to a high of $0.2186 (Aug 13, 2025), with a median of $0.1898 per EA.
Are there cheaper alternatives to CARBIDOPA-LEVO ER 50-200 TAB?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as CARBIDOPA-LEVO ER 50-200 TAB in a comparable dosage form, but none are currently priced below it.
Who manufactures CARBIDOPA-LEVO ER 50-200 TAB?
CARBIDOPA-LEVO ER 50-200 TAB (NDC 72888015630) is labeled by Advagen Pharma Ltd., and CMS classifies it as a generic product.